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Although a multitude of syndromes have been thoroughly described as a result of vitamin deﬁciencies, over consumption of
such substances may also be quite dangerous. Intratubular crystallization of calcium oxalate as a result of hyperoxaluria can
cause acute renal failure. This type of renal failure is known as oxalate nephropathy. Hyperoxaluria occurs as a result of inherited
enzymatic deﬁciencies known as primary hyperoxaluria or from exogenous sources known as secondary hyperoxaluria. Extensive
literature has reported and explained the mechanism of increased absorption of oxalate in malabsorptive syndromes leading to
renal injury. However, other causes of secondary hyperoxaluria may also take place either via direct dietary consumption of oxalate
rich products or via other substances which may metabolize into oxalate within the body. Vitamin C is metabolized to oxalate.
Oral or parenteral administration of this vitamin has been used in multiple settings such as an alternative treatment of malignancy
or as an immune booster. This article presents a clinical case in which ingestion of high amounts of vitamin C lead to oxalate
nephropathy. This article further reviews other previously published cases in order to illustrate and highlight the potential renal
harm this vitamin poses if consumed in excessive amounts.
1.Introduction
Acute renal failure can occur as a result of acute tubular
necrosis secondary to acute oxalate nephropathy due to the
deposition of calcium oxalate crystallization within the renal
tubules [1]. Oxalate nephropathy can occur in both pri-
mary and secondary hyperoxaluria. Primary hyperoxaluria
is a group of autosomal recessively inherited enzymatic
deﬁciencies that lead to the increased urinary excretion
of oxalate. In Type 1 primary hyperoxaluria, there is a
reduction of alanine:glyoxylate aminotransferase (AGT)
activity in the liver, leading to an accumulation of oxalate
[2]. Type 2 primary hyperoxaluria involves a mutation of
glyoxylate reductase/D-glycerate dehydrogenase, leading to
the excretion of increased amounts of L-glyceric acid as well
as oxalate [3].
Secondary hyperoxaluria can occur due to increased
dietary oxalate intake, increased absorption of oxalate from
the bowel (also known as enteric hyperoxaluria), and
increased production of oxalate.
Increased dietary intake of oxalate is fairly uncommon;
however, there have been case reports in the literature
describing excessive star fruit juice ingestion [4, 5]a n d
peanut intake [6] leading to oxalate nephropathy. Enteric
hyperoxaluria results mainly from fat malabsorption, which
leads to increased absorption of soluble oxalate from the
colon. Calcium binds to the free fatty acids that cannot
be absorbed. This reduces the normal calcium oxalate
precipitation in the feces thereby allowing the absorption of
soluble oxalate. This mechanism of enteric hyperoxaluria is
manifestedinseveralways,includingwithorlistattherapy[7,
8], Roux-en-Y gastric bypass surgery [9], celiac disease, and
Crohn’s disease. Increased production of oxalate is mainly
duetoincreasedlevelsofoxalateprecursors,morecommonly
glyoxylate, which is associated with ethylene glycol ingestion,
a n dl e s sc o m m o n l ya s c o r b i ca c i d[ 10]. We report, in detail, a
case of a patient who presented with this rare occurrence of
excessive vitamin C-induced oxalate nephropathy.
2. Case Presentation
Our patient is a 72-year-old white male who was brought
to the emergency department after being found down at
home and confused. On presentation, he was found to have2 International Journal of Nephrology
(a) (b)
Figure 1:(a)showsrenalcortexwithacutetubularinjury.(b)depictsthesameareaunderpolarizedlight.Thearrowsindicatethedeposition
of calcium oxalate crystals. H&E, ×200.
Table 1: Summary of biopsy proven cases of oxalate nephropathy secondary to ascorbic acid reported in the literature.
Patient
(Ref.
Num.)∗
Age Gender
Baseline Serum
creatinine
(mg/dl)
Renal presentation and
serum creatinine (Cr) in
mg/dl
Dose of
ascorbic acid
per day
Duration of
administration Treatment Outcome
20 71 Female 1.4 Anuria (Cr = 12.1) 500mg (oral) 6 months HD ESRD
15∗∗ 58 Female 1.0 Oliguria (Cr = 3.5 ) 45g (IV) 1 day HD Death
21∗∗∗ 72 Male Unknown Anuria(Cr = 15.3) Grams (oral) Months Medical Death
22 73 Male 1.2 Poor renal clearance
(Cr = 8.4) 680mg (oral) 4 months HD Recovery
Cr = 1.8mg/dl
23 31 Male Unknown Poor renal clearance
(Cr = 10.1)
2.5–5.0g
(oral)
Undisclosed
(week to
months?)
HD Recovery
Cr = 2.2mg/dl
24 49 Female 0.7 Oliguria (Cr = 4.5) 4.0g (oral) Several months HD Recovery
Cr = 1.1gm/dl
10 58 Male 1.4 Anuria (undisclosed) 1g (IV) 2 months HD Recovery
Cr = 1.4mg/dl
14 61 Male 1.3 Anuria (Cr = 13.3) 60g (IV) 1 day Medical Recovery
Cr = 2.9mg/dl
∗The ref. num. identiﬁes the individual case report. Please refer to the listed references at the end of the article to locate any particular case report by its
reference number.
∗∗The patient died from multiple organ failure. Her systemic illness was amyloidosis.
∗∗∗The patient died from renal failure and associated multiple organ failure as he did not want to undergo dialysis.
a BUN level of 102mg/dL, a creatinine level of 10.6mg/dL
(baseline BUN 3.6mg/dL and creatinine 1.3mg/dL), and
was also found to be oliguric. An ABG in the emergency
departmentshowedapHof7.19,PCO2of53,HCO3of21.4,
and a PO2 of 77mmHg on 2 liters of O2 via nasal cannula.
His acidosis was attributed to the patient’s history of COPD
and chronic CO2 retention. Urinalysis in the emergency
department showed 1 RBC/hpf, 1+ protein, and no WBC or
microorganisms present. Urine toxicology was positive for
prescribed opiates and negative for recreational substances,
including cocaine, ethanol, and amphetamines. The patient’s
ethyl alcohol and salicylate levels were undetectable. His
FeNa was calculated to be 1.7%. His measured serum osmo-
lality was 321mOsm/kg whereas his calculated osmolality
was 3mOsm/kg. Lab analysis also showed an elevated anion
gap of 19.
Further history was diﬃcult to attain given the fact that
the patient was only alert to person but not to place or
time. The patient was admitted to the medical ICU and the
nephrologyservicewasconsultedforfurtherevaluation.Due
to his poor renal clearance, he was initiated on hemodialysis
(HD).
The patient’s mental status improved after about a week,
andhiskidneyfunctioncontinuedtoslowlyimprove.During
his hospital stay, the patient was found to have negative p-
ANCA, c-ANCA, and qualitative ANA values. The patient’s
C3 and C4 levels were within normal limits.
However, despite continued supportive therapy, the
patient’s kidney function had not signiﬁcantly recovered as
expected. A renal biopsy was performed to shed further light
on his disease process. The pathology report of the renal
biopsy was consistent with ﬁndings of oxalate nephropathyInternational Journal of Nephrology 3
as numerous tubules showed birefringent crystals shaped as
plates or ﬁne spicules under polarized light (Figure 1). There
were also ﬁndings of moderate interstitial ﬁbrosis, mild-to-
moderate acute tubulointerstitial nephritis and mild hyaline
and hyperplastic arteriolosclerosis with moderate-to-severe
arteriosclerosis.
Upon further questioning, the patient denied ingestion
of any products containing ethylene glycol or any medica-
tions other than what was prescribed to him. He also denied
any prior gastric surgeries. However, the patient did mention
that he had changed his eating habits within the past year as
he wanted to include more leafy vegetables that incidentally
were rich in oxalate. He also admitted to ingesting between
1.9L and 3.8L per day of his favorite beverage for about
3-4 months prior to presentation. This beverage was an
orange ﬂavored powder drink, which had about 60mg of
vitamin C per 236.6mL serving. Therefore, the patient was
ingesting approximately 480mg to 960mg of vitamin C
daily. The patient’s oxalate nephropathy was attributed to
excessive vitamin C intake, which anecdotally has a poor
prognosis. As the biopsy demonstrated signiﬁcant interstitial
inﬂammation, prednisone was started at 60mg and tapered
down for a period of six weeks. The patient was discharged
from the hospital on HD. Five weeks after discharge, he was
able to be dialysis independent. His creatinine level at that
time was 1.9mg/dL.
3. Discussion
As described by Ralli et al. [11] in the 1930s, vitamin C
is excreted by the kidneys by ﬁltration and active tubular
reabsorption. The metabolism of vitamin C to oxalate
was later described in the 1960s by other investigators
[12, 13]. Since then, there have been several case reports
in the literature mentioning acute oxalate nephropathy in
association with excessive vitamin C intake. Wong et al. [19]
reports a patient with metastatic carcinoma of the prostate
with underlying obstructive renal insuﬃciency who received
a 60gm bolus of IV vitamin C an an alternative therapy and
developedanuricrenalfailure.Twodayslateronrenalbiopsy,
the patient had similar ﬁndings to our patient. Lawton et
al. [14] also describes a patient with similar ﬁndings after
a single administration of 45gm of IV ascorbic acid as
adjuvant therapy for primary amyloidosis with nephrotic
syndrome.
In the 1970s, Sullivan and Eisenstein [15, 16]d e m o n -
strated that dialysis patients tended to lose ascorbic acid
during dialysis and as a result, should receive vitamin
C supplementation. Subsequently, there have been reports
of cases of patients on dialysis who developed oxalate
crystal deposition in various organs secondary to vitamin C
supplementation [17].
Vitamin C induced acute oxalate nephropathy has also
been reported in the setting of patients who received par-
enteral alimentation. Friedman and associates [18]d e s c r i b e
a patient with hemolytic uremic syndrome who was given
t o t a lp a r e n t e r a ln u t r i t i o n( w h i c hi n c l u d e d5 0 0 m g / d a yo f
ascorbic acid) while in the hospital. The patient ended up
passing away with sepsis and severe metabolic acidosis about
4 months after being admitted. An autopsy showed extensive
deposition of calcium oxalate in the kidneys and pancreas.
Table 1 provides a summary of the various cases reported
in the literature of biopsy proven oxalate nephropathy
suspected to be secondary to ascorbic acid [10, 14, 19–24].
Our patient’s renal biopsy ﬁndings were similar to the
biopsy ﬁndings mentioned in the cases above. Although
vitamin C induced hyperoxaluria is not as common as
ingestion of ethylene glycol leading to oxalate nephropathy,
clinicians must consider the potential dangers of large dose
ingestion of vitamin C in some individuals, especially those
with underlying kidney disease or advanced age.
In conclusion, the use of vitamin C must be scrutinized
closely both in patients with normal renal function and
with underlying renal insuﬃciency. According to Auer et al.
[25], “surveys have indicated that about 66% of the general
public take ascorbic acid either on its own or as part of a
multivitaminpreparationandthatingestionofmegadosesof
this vitamin in excess of the recommended daily allowance
is common”. This ﬁgure is extremely concerning given
the increasing percentage of the general public developing
chronic kidney disease. We would like to add our case
presentation to the literature as further evidence of this
overlookedissue.Additionally,consideringtheimprovement
ofourpatient’sconditionafterbeingtreatedempiricallywith
prednisone, it is crucial to further investigate the potential
beneﬁts and improvement of prognosis with prednisone
therapy in the setting of oxalate nephropathy.
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